Literature DB >> 33907617

Steroid use and misuse: a key performance indicator in the management of IBD.

Jonathan Blackwell1,2, Christian Selinger3,4, Tim Raine5, Gareth Parkes6, Melissa A Smith7,8, Richard Pollok1,9.   

Abstract

Corticosteroids remain an important tool for inducing remission in inflammatory bowel disease (IBD) but they have no role in maintenance of remission. The significant adverse side effect profile of these drugs means their use should be avoided where possible or measures taken to reduce their risk. Despite an expanding array of alternative therapies, corticosteroid dependency and excess remain common. Appropriate steroid use is now regarded a key performance indicator in the management of IBD. This article aims to outline indications for corticosteroid use in IBD, their risks and strategies to reduce their use and misuse. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  5-aminosalicylic acid (5-ASA); crohn's disease; inflammatory bowel disease; steroid-sparing efficacy; ulcerative colitis

Year:  2020        PMID: 33907617      PMCID: PMC8040510          DOI: 10.1136/flgastro-2019-101288

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  86 in total

1.  PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION.

Authors:  J E LENNARD-JONES; J J MISIEWICZ; A M CONNELL; J H BARON; F A JONES
Journal:  Lancet       Date:  1965-01-23       Impact factor: 79.321

Review 2.  Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis.

Authors:  Leonie H A Broersen; Alberto M Pereira; Jens Otto L Jørgensen; Olaf M Dekkers
Journal:  J Clin Endocrinol Metab       Date:  2015-04-06       Impact factor: 5.958

Review 3.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

Review 4.  Regulation of gluconeogenesis by glucocorticoids.

Authors:  J H Exton
Journal:  Monogr Endocrinol       Date:  1979

5.  Steroid dependency and pediatric inflammatory bowel disease in the era of immunomodulators--a population-based study.

Authors:  Christian Jakobsen; Pia Munkholm; Anders Paerregaard; Vibeke Wewer
Journal:  Inflamm Bowel Dis       Date:  2010-12-03       Impact factor: 5.325

6.  Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis.

Authors:  Manuel Barreiro-de Acosta; Aurelio Lorenzo; Jose Mera; J Enrique Dominguez-Muñoz
Journal:  J Crohns Colitis       Date:  2009-12       Impact factor: 9.071

Review 7.  Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.

Authors:  Antje Timmer; Petrease H Patton; Nilesh Chande; John W D McDonald; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2016-05-18

8.  Corticosteroids reduce regenerative repair of epithelium in experimental gastric ulcers.

Authors:  M Carpani de Kaski; R Rentsch; S Levi; H J Hodgson
Journal:  Gut       Date:  1995-11       Impact factor: 23.059

9.  Withdrawal of corticosteroids in inflammatory bowel disease patients after dependency periods ranging from 2 to 45 years: a proposed method.

Authors:  S J Murphy; L Wang; L A Anderson; A Steinlauf; D H Present; J I Mechanick
Journal:  Aliment Pharmacol Ther       Date:  2009-09-04       Impact factor: 8.171

10.  Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy.

Authors:  H O Conn; T Poynard
Journal:  J Intern Med       Date:  1994-12       Impact factor: 8.989

View more
  1 in total

1.  Biologic therapy for Crohn's disease over the last 3 decades.

Authors:  Ji-Liang Shen; Zheng Zhou; Jia-Sheng Cao; Bin Zhang; Jia-Hao Hu; Jia-Ying Li; Xiao-Ming Liu; Sarun Juengpanich; Ming-Song Li; Xu Feng
Journal:  World J Clin Cases       Date:  2022-01-14       Impact factor: 1.337

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.